More on GSD
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $11.25 |
|
|||
| Open | $161.75 | ||||
| 52 Wk High | $28.34 | ||||
| 52 Wk Low | $21.57 | ||||
| Day High | $11.25 | ||||
| Day Low | $11.25 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 1,007,437 | ||||
- Devonian Reports Results of its Annual General and Special Meeting of Shareholders
- Devonian Health Group Inc. Reports Financial and Operating Results of its Three and Six Months Ended January 31, 2026
- Devonian Reports Human Liver-on-a-Chip Data Demonstrating Disease-Relevant Modulation of MASH by Thykamine™, with Dose-Dependent Anti-Fibrotic and Anti-Inflammatory Effects
- Devonian Advances Thykamine™ Patent Strategy with Proprietary Fingerprint and Robust Manufacturing Controls
- Devonian reports additional molecular data from MASH liver study
- Devonian Health shows positive preclinical results for lung fibrosis drug
- DEVONIAN REPORTS POSITIVE RESULTS IN PULMONARY FIBROSIS STUDY
- Devonian Health Group names Dennis Turpin as chief financial officer
- DEVONIAN APPOINTS DENNIS TURPIN AS CHIEF FINANCIAL OFFICER AND PROVIDES UPDATES ON STOCK OPTIONS GRANT
- DEVONIAN ANNOUNCES SHARE CONSOLIDATION IN FURTHER PREPARATION FOR POTENTIAL U.S. LISTING
Entities mentioned with GSD
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- SPAC | View Related Stories »
- 13G | View Related Stories »
- Earnings | View Related Stories »
- IPO | View Related Stories »
- Twitter | View Related Stories »
- S3 | View Related Stories »
- Show More...
